Literature DB >> 33331926

Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.

Hongzhi Miao1, EunGi Kim1, Dong Chen1, Trupta Purohit1, Katarzyna Kempinska1, James Ropa2, Szymon Klossowski1, Winifred Trotman3, Gwenn Danet-Desnoyers3, Tomasz Cierpicki1, Jolanta Grembecka1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33331926      PMCID： PMC7751359          DOI： 10.1182/blood.2020006575

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  25 in total

1.  Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction.

Authors:  Dmitry Borkin; Szymon Klossowski; Jonathan Pollock; Hongzhi Miao; Brian M Linhares; Katarzyna Kempinska; Zhuang Jin; Trupta Purohit; Bo Wen; Miao He; Duxin Sun; Tomasz Cierpicki; Jolanta Grembecka
Journal:  J Med Chem       Date:  2018-05-23       Impact factor: 7.446

2.  Menin critically links MLL proteins with LEDGF on cancer-associated target genes.

Authors:  Akihiko Yokoyama; Michael L Cleary
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

3.  Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.

Authors:  Dmitry Borkin; Shihan He; Hongzhi Miao; Katarzyna Kempinska; Jonathan Pollock; Jennifer Chase; Trupta Purohit; Bhavna Malik; Ting Zhao; Jingya Wang; Bo Wen; Hongliang Zong; Morgan Jones; Gwenn Danet-Desnoyers; Monica L Guzman; Moshe Talpaz; Dale L Bixby; Duxin Sun; Jay L Hess; Andrew G Muntean; Ivan Maillard; Tomasz Cierpicki; Jolanta Grembecka
Journal:  Cancer Cell       Date:  2015-03-26       Impact factor: 31.743

4.  Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.

Authors:  Ronald W Stam; Monique L den Boer; Pauline Schneider; Peter Nollau; Martin Horstmann; H Berna Beverloo; Ella van der Voort; Maria G Valsecchi; Paola de Lorenzo; Stephen E Sallan; Scott A Armstrong; Rob Pieters
Journal:  Blood       Date:  2005-06-14       Impact factor: 22.113

5.  Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.

Authors:  Margarita M Dzama; Marlene Steiner; Johanna Rausch; Daniel Sasca; Jonas Schönfeld; Kerstin Kunz; Martha C Taubert; Gerard M McGeehan; Chun-Wei Chen; Annalisa Mupo; Patricia Hähnel; Matthias Theobald; Thomas Kindler; Richard P Koche; George S Vassiliou; Scott A Armstrong; Michael W M Kühn
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

6.  Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner.

Authors:  S He; B Malik; D Borkin; H Miao; S Shukla; K Kempinska; T Purohit; J Wang; L Chen; B Parkin; S N Malek; G Danet-Desnoyers; A G Muntean; T Cierpicki; J Grembecka
Journal:  Leukemia       Date:  2015-06-18       Impact factor: 11.528

7.  A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.

Authors:  Andrei V Krivtsov; Kathryn Evans; Jayant Y Gadrey; Benjamin K Eschle; Charlie Hatton; Hannah J Uckelmann; Kenneth N Ross; Florian Perner; Sarah N Olsen; Tara Pritchard; Lisa McDermott; Connor D Jones; Duohui Jing; Ali Braytee; Diego Chacon; Eric Earley; Brian M McKeever; David Claremon; Andrew J Gifford; Heather J Lee; Beverly A Teicher; John E Pimanda; Dominik Beck; Jennifer A Perry; Malcolm A Smith; Gerard M McGeehan; Richard B Lock; Scott A Armstrong
Journal:  Cancer Cell       Date:  2019-12-09       Impact factor: 31.743

8.  Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.

Authors:  Szymon Klossowski; Hongzhi Miao; Katarzyna Kempinska; Tao Wu; Trupta Purohit; EunGi Kim; Brian M Linhares; Dong Chen; Gloria Jih; Eric Perkey; Huang Huang; Miao He; Bo Wen; Yi Wang; Ke Yu; Stanley Chun-Wei Lee; Gwenn Danet-Desnoyers; Winifred Trotman; Malathi Kandarpa; Anitria Cotton; Omar Abdel-Wahab; Hongwei Lei; Yali Dou; Monica Guzman; Luke Peterson; Tanja Gruber; Sarah Choi; Duxin Sun; Pingda Ren; Lian-Sheng Li; Yi Liu; Francis Burrows; Ivan Maillard; Tomasz Cierpicki; Jolanta Grembecka
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

Review 9.  Targeting FLT3 mutations in AML: review of current knowledge and evidence.

Authors:  Naval Daver; Richard F Schlenk; Nigel H Russell; Mark J Levis
Journal:  Leukemia       Date:  2019-01-16       Impact factor: 11.528

Review 10.  Clustering Algorithms: Their Application to Gene Expression Data.

Authors:  Jelili Oyelade; Itunuoluwa Isewon; Funke Oladipupo; Olufemi Aromolaran; Efosa Uwoghiren; Faridah Ameh; Moses Achas; Ezekiel Adebiyi
Journal:  Bioinform Biol Insights       Date:  2016-11-30
View more
  5 in total

1.  Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.

Authors:  Bing Z Carter; Wenjing Tao; Po Yee Mak; Lauren B Ostermann; Duncan Mak; Gerard McGeehan; Peter Ordentlich; Michael Andreeff
Journal:  Blood       Date:  2021-10-28       Impact factor: 22.113

2.  Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).

Authors:  Warren Fiskus; Steffen Boettcher; Naval Daver; Christopher P Mill; Koji Sasaki; Christine E Birdwell; John A Davis; Koichi Takahashi; Tapan M Kadia; Courtney D DiNardo; Qi Jin; Yuan Qi; Xiaoping Su; Gerard M McGeehan; Joseph D Khoury; Benjamin L Ebert; Kapil N Bhalla
Journal:  Blood Cancer J       Date:  2022-01-11       Impact factor: 9.812

Review 3.  Updates on the Management of Acute Myeloid Leukemia.

Authors:  Sofía Huerga-Domínguez; Sara Villar; Felipe Prósper; Ana Alfonso-Piérola
Journal:  Cancers (Basel)       Date:  2022-09-29       Impact factor: 6.575

Review 4.  Targeted therapy in NPM1-mutated AML: Knowns and unknowns.

Authors:  Rong Wang; Pan Xu; Lin-Lin Chang; Shi-Zhong Zhang; Hong-Hu Zhu
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

Review 5.  Current status and future perspectives in targeted therapy of NPM1-mutated AML.

Authors:  Roberta Ranieri; Giulia Pianigiani; Sofia Sciabolacci; Vincenzo Maria Perriello; Andrea Marra; Valeria Cardinali; Sara Pierangeli; Francesca Milano; Ilaria Gionfriddo; Lorenzo Brunetti; Maria Paola Martelli; Brunangelo Falini
Journal:  Leukemia       Date:  2022-08-25       Impact factor: 12.883
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.